ATE287717T1 - Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung - Google Patents
Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigungInfo
- Publication number
- ATE287717T1 ATE287717T1 AT97950607T AT97950607T ATE287717T1 AT E287717 T1 ATE287717 T1 AT E287717T1 AT 97950607 T AT97950607 T AT 97950607T AT 97950607 T AT97950607 T AT 97950607T AT E287717 T1 ATE287717 T1 AT E287717T1
- Authority
- AT
- Austria
- Prior art keywords
- estrogen
- prevention
- treatment
- ischemic injury
- population
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dentistry (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/749,703 US5877169A (en) | 1993-11-05 | 1996-11-15 | Methods of treatment of ischemic damage |
| PCT/US1997/020875 WO1998022113A1 (en) | 1996-11-15 | 1997-11-14 | Methods of prevention and treatment of ischemic damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE287717T1 true ATE287717T1 (de) | 2005-02-15 |
Family
ID=25014823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97950607T ATE287717T1 (de) | 1996-11-15 | 1997-11-14 | Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5877169A (de) |
| EP (1) | EP0942736B1 (de) |
| JP (1) | JP2001504488A (de) |
| KR (1) | KR20000053321A (de) |
| AT (1) | ATE287717T1 (de) |
| CA (1) | CA2271273A1 (de) |
| DE (1) | DE69732367D1 (de) |
| WO (1) | WO1998022113A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350739B1 (en) * | 1999-08-11 | 2002-02-26 | University Of Florida Resarch Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
| US6319914B1 (en) * | 1993-11-05 | 2001-11-20 | Apollo Biopharmaceuticals, Inc. | Cytoprotective effect of polycyclic phenolic compounds |
| US20060264357A1 (en) * | 1997-04-22 | 2006-11-23 | Zikria Bashir A | Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
| WO2000028982A2 (en) | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
| US6339078B1 (en) * | 1999-07-20 | 2002-01-15 | University Of Florida Research Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
| US6326365B1 (en) | 1999-07-20 | 2001-12-04 | Apollo Biopharmaceutics, Inc. | Methods of prevention and treatment of ischemic damage |
| WO2002000619A2 (en) * | 2000-06-27 | 2002-01-03 | University Of Florida Research Foundation, Inc. | Alkyl ether modified polycyclic compounds having a terminal phenol as cell protecting agents |
| GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| WO2002013870A2 (en) * | 2000-08-17 | 2002-02-21 | Mitokor, Inc. | Formulation for administering therapeutic lipophilic molecules |
| CA2427817C (en) * | 2000-11-03 | 2009-04-14 | Washington University | Estrone-derivatives having cytoprotective activity |
| EP1834959B1 (de) | 2000-11-03 | 2012-08-08 | Washington University | Tert-butyl-substituierte aromatische Steroide mit zytoprotektiver Wirkung |
| WO2002040032A2 (en) * | 2000-11-17 | 2002-05-23 | Washington University | Cytoprotective estrogen derivatives |
| US20030216329A1 (en) * | 2001-04-24 | 2003-11-20 | Robinson Cynthia B. | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
| EP1423509A2 (de) * | 2001-08-30 | 2004-06-02 | Stem Cell Therapeutics Inc. | Differenzierung von neuralen stammzellen und therapeutische anwendung |
| US20040214806A1 (en) * | 2002-09-03 | 2004-10-28 | Iok-Hou Pang | Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma |
| US7488723B2 (en) | 2001-09-05 | 2009-02-10 | Alcon, Inc. | Use of non-feminizing estrogens as treatment for retinal vascular diseases |
| EP1430114B1 (de) | 2001-09-14 | 2012-01-18 | Stem Cell Therapeutics Inc. | Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung |
| AR036402A1 (es) * | 2001-09-18 | 2004-09-08 | Stem Cell Therapeutics Inc | Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales. |
| AU2002359635A1 (en) * | 2001-12-05 | 2003-06-17 | Mitokor, Inc. | Use of polycyclic phenolic compounds for the treatment of opthalmic diseases |
| US6903220B2 (en) * | 2002-05-15 | 2005-06-07 | Genzyme Corporation | Synthesis of chiral 2-alkyl amino acids |
| WO2004011497A1 (en) * | 2002-07-31 | 2004-02-05 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
| US20070111932A1 (en) * | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| ES2392282T3 (es) * | 2004-02-13 | 2012-12-07 | Stem Cell Therapeutics Corp. | Uso de la hormona luteinizante (LH) y de la gonadotropina coriónica (hCG) para la proliferación de células precursoras neurales y la neurogénesis |
| US7304171B2 (en) * | 2004-05-27 | 2007-12-04 | Migenix Corp. | Compounds and methods for cytoprotection |
| US7304073B2 (en) * | 2004-08-20 | 2007-12-04 | Wyeth | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors |
| KR20080074108A (ko) | 2005-09-27 | 2008-08-12 | 스템 셀 테라퓨틱스 코포레이션 | 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식 |
| WO2007106986A1 (en) * | 2006-03-17 | 2007-09-27 | Stem Cell Therapeutics Corp. | Dosing regimes for lh or hcg and epo for treatment of neurological disorders |
| US20070287684A1 (en) | 2006-05-22 | 2007-12-13 | Irshad Chaudry | Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof |
| WO2013172969A1 (en) | 2012-05-15 | 2013-11-21 | The Uab Research Foundation | Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05178883A (ja) * | 1991-09-27 | 1993-07-20 | Oyo Seikagaku Kenkyusho | カテコールエストロゲンのシクロデキストリン包接複合体及びその用途 |
| US5587369A (en) * | 1993-03-09 | 1996-12-24 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| DE4319096C1 (de) * | 1993-06-08 | 1994-09-08 | Kuhl Herbert Prof Dr Phil Nat | Hormonales Mittel zur Vorbeugung und Behandlung arterieller Erkrankungen beim Mann |
| US5512557A (en) * | 1993-10-07 | 1996-04-30 | National Heart And Lung Institute | Coronary heart disease treated with 17βoestradiol |
| WO1995005826A1 (en) * | 1993-08-20 | 1995-03-02 | Jackson Meyer B | Method for regulating neuropeptide hormone secretion |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| DE4338314C1 (de) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen |
| JPH08165242A (ja) * | 1994-12-09 | 1996-06-25 | Kunio Yagi | 抗動脈硬化剤 |
| DE19524937A1 (de) * | 1995-07-08 | 1997-01-09 | Jenapharm Gmbh | Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann |
-
1996
- 1996-11-15 US US08/749,703 patent/US5877169A/en not_active Expired - Fee Related
-
1997
- 1997-11-14 KR KR1019990704323A patent/KR20000053321A/ko not_active Ceased
- 1997-11-14 DE DE69732367T patent/DE69732367D1/de not_active Expired - Lifetime
- 1997-11-14 JP JP52376498A patent/JP2001504488A/ja not_active Ceased
- 1997-11-14 WO PCT/US1997/020875 patent/WO1998022113A1/en not_active Ceased
- 1997-11-14 AT AT97950607T patent/ATE287717T1/de not_active IP Right Cessation
- 1997-11-14 EP EP97950607A patent/EP0942736B1/de not_active Expired - Lifetime
- 1997-11-14 CA CA002271273A patent/CA2271273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0942736B1 (de) | 2005-01-26 |
| JP2001504488A (ja) | 2001-04-03 |
| CA2271273A1 (en) | 1998-05-28 |
| EP0942736A1 (de) | 1999-09-22 |
| WO1998022113A1 (en) | 1998-05-28 |
| DE69732367D1 (de) | 2005-03-03 |
| KR20000053321A (ko) | 2000-08-25 |
| US5877169A (en) | 1999-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69732367D1 (de) | Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung | |
| DE69529577D1 (de) | Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung | |
| ATE236654T1 (de) | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten | |
| ATE269066T1 (de) | Kombinationstherapie zur prophylaxe und/oder behandlung von gutartiger prostatischer hyperplasie | |
| ATE212546T1 (de) | Behandlung von neurodegenerativen zuständen mittels nimesulide | |
| DE69726245D1 (de) | Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| BG100510A (bg) | Метод за лечение на андрогенна алопеция с инхибитори на 5-алфа редуктаза | |
| EA200200132A1 (ru) | СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ | |
| BR9808221A (pt) | Método de tratamento de tumor. | |
| FR2391732A1 (fr) | Composition pharmaceutique pour l'usage dentaire | |
| ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
| DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| EP0992243A4 (de) | Stoff für die prophylaxe oder therapie | |
| ATE297739T1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
| DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
| EP0757697A4 (de) | Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges | |
| DE69623316D1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
| LV11593A (lv) | Dimetikona pielietojums aizcietejumu arstesana | |
| ATE236633T1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
| MX9701606A (es) | Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno. | |
| ATE271867T1 (de) | Behandlung der harninkontinenz und zusammenstellung dafür |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |